Molecular mimicry of host structures by lipopolysaccharides of Campylobacter and Helicobacter spp.: Implications in pathogenesis

Journal of Endotoxin Research

Volumn 3, Issue 6, 1996, Pages 521-531

  Moran, A P ^a   Appelmelk, B J ^b   Aspinall, G O ^c  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); CAMPYLOBACTER; CAMPYLOBACTER JEJUNI; HAEMOPHILUS; HELICOBACTER; HELICOBACTER PYLORI; NEISSERIA;

AUTOANTIBODY; GANGLIOSIDE; LIPOPOLYSACCHARIDE;

AUTOIMMUNITY; BLOOD GROUP LEWIS SYSTEM; CAMPYLOBACTER JEJUNI; CROSS REACTION; ENTERITIS; ETIOLOGY; GASTRITIS; GUILLAIN BARRE SYNDROME; HELICOBACTER PYLORI; HUMAN; IMMUNOREGULATION; REVIEW; SEROTYPE; STOMACH MUCOSA;

EID: 0030452757     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1177/096805199600300611     Document Type: Review

References (127)

1. Rietschel E.T., Brade L, Schade U. et al. Chemical structure and biological activity of lipopolysaccharides. In: Baumgartner J.D., Calandra T., Carlet J. (Eds) Endotoxin: From Pathophysiology to Therapeutic Approaches. Paris: Médecine-Sciences Flammarion 1990; 5-18.
2. Moran A.P. Structure-bioactivity relationships of bacterial endotoxins. J Toxicol Toxin Rev 1995; 14: 47-83.
3. Rietschel E.T., Brade L, Holst O. et al. Molecular structure of bacterial endotoxin in relation to bioactivity. In: Nowotny A., Spitzer J.J., Ziegler E.J., (Eds) Endotoxin Research Series, Vol. 1: Cellular and Molecular Aspects of Endotoxin Reactions. Amsterdam: Elsevier, 1990; 15-32.
4. Mandrell R.E., Apicella M.A. Lipo-oligosaccharides (LOS) of mucosal pathogens: molecular mimicry and host-modification of LOS. Immunobiology 1993; 187: 382-402.
5. Moran A.P., Prendergast M.M., Appelmelk B.J. Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. FEMS Immunol Med Microbiol 1996; In press.
6. Jann K., Jann, B. Polysaccharide antigens of Escherichia coli. Rev Infect Dis 1987; 9 (Suppl): S517-S526.
7. Patel P.V., Parsons N.J., Andrade J.R.C. et al. White blood cells including polymorphonuclear phagocytes contain a factor which induces gonococcal resistance to complement-mediated serum killing. FEMS Microbiol Lett 1988; 50: 173-176.
8. Rest R.F., Frangipane J.V. Growth of Neisseria gonorrhoeae in CMP-N-acetylneuraminic acid inhibits nonopsonic (opacity-associated outer membrane protein-mediated) interactions with human neutrophils. Infect Immun 1992; 60: 989-997.
9. Wetzler L.M., Barry K., Blake M.S., Gotschlich E.C. Gonococcal lipooligosaccharide sialylation prevents complement-dependent killing by immune sera. Infect Immun 1992; 60: 39-43.
10. Moran A.P. The role of lipopolysaccharide in Helicobacter pylori pathogenesis. Aliment Pharmacol Ther 1996; 10 (Suppl. 1): 39-50.
11. Skirrow M.B. Campylobacter enteritis: a "new" disease. BMJ 1977; 2: 9-11.
12. Nachamkin I., Blaser M.J., Tompkins L.S. (Eds) Campylobacter jejuni: Current Status and Future Trends. Washington, DC: American Society for Microbiology, 1992.
13. Rhodes K.M., Tattersfield A.E. Guillain-Barré syndrome associated with Campylobacter infection. BMJ 1982; 285: 173-174.
14. Hughes R.A.C. (Ed) Guillain-Barré Syndrome. London: Springer, 1990.
15. Alter M. The epidemiology of Guillain-Barré syndrome. Ann Neurol 1990; 27 (Suppl.): S7-S12.
16. Mishu B., Blaser M.J. Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barré syndrome. Clin Infect Dis 1993; 17: 104-108.
17. Mishu B., Ilyas A.A., Koski C.L. et al. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome. Ann Intern Med 1993; 118: 947-953.
18. Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A.C. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995; 333: 1374-1379.
19. Coe C.J. Guillain-Barré syndrome in Korean children. Yonseri Med J 1989; 30: 81-87.
20. Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990; 40: 1900-1902.
21. Wadia R.S. Acute paralytic disease. Lancet 1992; 339: 993.
22. McKhann G.M., Cornblath D.R., Griffin J.W. et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993; 33: 333-342.
23. Blaser M.J., Olivares A., Taylor D.N., Cornblath D.R., McKhann G.M. Campylobacter serology in patients with Chinese paralytic syndrome. Lancet 1991; 338: 308.
24. Penner J.L., Hennessy J.N. Passive hemagglutination technique for serotyping Campylobacter fetus svbsp. jejuni on the basis of soluble, heat-stable antigens. J Clin Microbiol 1980; 12: 732-737.
25. Moran A.P., Kosunen T.U. Serological analysis of the heat-stable antigens involved in serotyping Campylobacter jejuni and Campylobacter call. APMIS 1989; 97: 253-260.
26. Fujimoto S., Yuki N., Itoh T., Amako K. Specific serotype of Campylobacter jejuni associated with Guillain-Barré syndrome. J Infect Dis 1992; 165: 183.
27. Kuroki S., Saida T., Nukina M. et al. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain β-N-acetylglucosamine residues. Ann Neurol 1993; 33: 243-247.
28. Yuki N., Tsujino Y. Familial Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. J Pediatr 1995; 126: 162.
29. Mishu B., Ho T.W., Li C.Y. et al. Guillain-Barré syndrome (GBS), acute motor axonal neuropathy and C. jejuni infection. Acta Gastroenterol Belg 1993; 56 (Suppl.): 9.
30. Moran A.P., O'Malley D.T. Potential role of lipopolysaccharides of Campylobacter jejuni in the development of Guillain-Barré syndrome. J Endotoxin Res 1995; 2: 233-235.
31. Oomes P.G., Jacobs B.C., Hazenberg M.P.H., Bänffer J.R.J., van der Meché F.G.A. Anti-GM1 IgG antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann Neurol 1995; 38: 170-175.
32. Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A.C. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995; 333: 1374-1379.
33. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956; 255: 57-65.
34. Yuki N., Taki T., Takahashi M. et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994; 36: 791-793.
35. 1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann Neurol 1995; 37: 260-264.
36. 3. Infect Immun 1996; 64: 2945-2949.
37. Preston M.A., Penner J.L. Structural and antigenic properties of lipopolysaccharides from serotype reference strains of Campylobacter jejuni. Infect Immun 1987; 55: 1806-1812.
38. Blake D.C., Russell R.G. Demonstration of lipopolysaccharide with O-polysaccharide chains among different heat-stable serotypes of Campylobacter jejuni by silver staining of polyacrylamide gels. Infect Immun 1993; 61: 5384-5387.
39. Aspinall G.O., McDonald A.G., Pang H. Structures of the O chains from lipopolysaccharides of Campylobacter jejuni serotypes O:23 and O:36. Carbohydr Res 1992; 231: 13-30.
40. Aspinall G.O., McDonald A.G., Pang H. Lipopolysaccharides of Campylobacter jejuni O:19: structures of O antigen chains from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 1994; 33: 250-255.
41. Aspinall G.O., McDonald A.G., Raju T.S., Pang H., Moran A.P., Penner J.L. Chemical structure of the core regions of Campylobacter jejuni serotypes O:1, O:4, and O:23 and O:36 lipopolysaccharides. Eur J Biochem 1993; 213: 1017-1027.
42. Aspinall G.O., McDonald A., Raju T.S. et al. Chemical structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide. Eur J Biochem 1993; 213: 1029-1037.
43. Aspinall G.O., Lynch C.M., Pang H., Shaver R.T., Moran A.P. Chemical structures of the core region of Campylobacter jejuni O:3 lipopolysaccharide and an associated polysaccharide. Eur J Biochem 1995; 231: 570-578.
44. Nobile-Oraz E., Carpo M., Scarlato G. Gangliosides: their role in clinical neurology. Drugs 1994; 47: 576-585.
45. 1 and lipopolysaccharide from Tenner's serotype 19 of Campylobacter jejuni. Biomed Res 1992; 13: 451453.
46. Yuki N., Taki X, Inagaki F. et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GMl ganglioside-like structure. J Exp Med 1993; 178: 1771-1775.
47. Aspinall G.O., McDonald A.G., Pang H., Kurjanczyk L.A., Penner J.L. Lipopolysaccharides of Campylobacter jejuni O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 1994; 33: 241-249.
48. Yuki N., Handa S., Tai T. et al. Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain-Barré syndrome. J Neurol Sci 1995; 130: 112-116.
49. Moran A.P., Rietschel E.T., Kosunen T.U., Zähringer U. Chemical characterization of Campylobacter jejuni lipopolysaccharides containing N-acetylneuraminic acid and 2,3-diamino-2,3-dideoxy-D-glucose. J Bacteriol 1991; 173: 618-626.
50. Moran A.P. Biological and serological characterization of Campylobacter jejuni lipopolysaccharides with deviating core and lipid A structures. FEMS Immun Med Microbiol 1995; 11: 121-130.
51. Yuki N., Taki T., Takahashi M. et al. Penner's serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope. Infect Immun 1994; 62: 2101-2103.
52. Schwerer B., Neisser A., Poll R.J., Bernheimer H., Moran A.P. Antibody cross-reactivities between gangliosides and lipopolysaccharides of Campylobacter jejuni serotypes associated with Guillain-Barré syndrome. J Endotoxin Res 1995; 2: 395-403.
53. 2 ganglioside after immunization with lipopolysaccharides from Campylobacter jejuni. Int J Cancer 1996; 66: 184-190.
54. van der Meché F.G.A., Schmitz P.I.M., the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-1129.
55. Figueras A., Morales-Olivas F.J., Capella D., Palop V., Laporte J.R. Bovine gangliosides and acute motor polyneuropathy. BMJ 1992; 305: 1330-1331.
56. Illa I., Ortiz N., Gallard E., Juarez C., Grau J.M., Dalakas M.C. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Amt Neurol 1995; 38: 218-224.
57. Wirguin I, Suturkova-Milosevic L, Della-Latta P., Fisher T., Brown R.H., Latov N. Monoclonal IgM antibodies to GM1 and asialo-GM1 in chronic neuropathies cross-react with Campylobacter jejuni lipopolysaccharides. Ann Neurol 1994; 35: 698-703.
58. Sadiq S.A., Thomas P.P., Kilidireas K. et al. The spectrum of neurological disease associated with anti-GM1 antibodies. Neurology 1990; 40: 327-330.
59. +. Neurology 1991; 40 (Suppl. 1): 367.
60. Daikoku T., Kawaguchi M., Takama K., Suzuki S. Partial purification and characterization of the enterotoxin produced by Campylobacter jejuni. Infect Immun 1990; 58: 2414-2419.
61. Yuki N., Sato S., Itoh T., Miyatake T. HLA-B35 and acute axonal polyneuropathy following Campylobacter infection. Neurology 1991; 41: 1561-1563.
62. Yuki N. Pathogenesis of axonal Guillain-Barré syndrome: hypothesis. Muscle Nerve 1994; 17: 680-682.
63. Thomas P.P., Trojaborg W, Nagy C. et al. Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier. Acta Neuropathol 1991; 82: 378-383.
64. Illa I., Ortiz N., Gallard E., Juarez C., Grau J.M., Dalakas M.C. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 1995; 38: 218-224.
65. Waxman S.G. Sodium channel blockade by antibodies: a new mechanism of neurological disease. Ann Neurol 1995; 37: 421-423.
66. Griffin J.W., Li C.Y., Macko C. et al. Early nodal changes in the acute motor axonal neuropathy pattern of Guillain-Barré syndrome. J Neurocytol 1996; 25: 33-51.
67. Warren J.R., Marshall B. Unidentified curved bacillus on gastric epithelium in active chronic gastritis. Lancet 1983; i: 1273-1275.
68. Taylor D.N., Blaser M.J. The epidemiology of Helicobacter pylori infection. Epidemiol Rev 1991; 13: 42-59.
69. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; i: 1311-1315.
70. Rauws E.A.J., Langenberg W., Houthoff H.J., Zanen H.C., Tytgat G.N.J. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33-40.
71. Graham D.Y., Lew G.M., Klein P.D. et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. Ann Intern Med 1992; 116: 705-708.
72. Rauws E.A.J., Tytgat G.N.J. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335: 1233-1235.
73. Kuipers E.J., Thijs J.C., Festen H.P.M. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 (Suppl. 2): 53-58.
74. Forman D., Newell D.G., Fullerton F. et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991; 302: 1302-1305.
75. Nomura A., Stemmermann G.N., Chyou P.H., Kato I, Perez-Perez G.I., Blaser M.J. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325: 1132-1136.
76. Parsonnet, J., Hansen S., Rodriguez L. et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330: 1267-1271.
77. Wotherspoon A.C., Ortiz-Hidalgo C., Falton M.R., Isaacson P.G. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175-1176.
78. Moran A.P. Pathogenic properties of Helicobacter pylori. Scand J Gastroenterol 1996; 31 (Suppl. 215): 22-31.
79. Crabtree J.E. Immune and inflammatory responses to Helicobacter pylori infection. Scand J Gastroenterol 1996; 31 (Suppl. 215): 3-10.
80. Muotiala A., Heiander I.M., Pyhälä L, Kosunen T.U., Moran A.P. Low biological activity of Helicobacter pylori lipopolysaccharide. Infect Immun 1992; 60: 1714-1716.
81. Young G.O., Stemmet N., Lastovica A. et al. Helicobacter pylori lipopolysaccharide stimulates gastric mucosal pepsinogen secretion. Aliment Pharmacol Ther 1992; 6: 169-177.
82. Moran A.P. Cell surface characteristics of Helicobacter pylori. FEMS Immunol Med Microbiol 1995; 10: 271-280.
83. Pearson J.P., Ward R., Allen A., Roberts N.B., Taylor W.H. Mucus degradation by pepsin. Comparison of mucolytic activity of human pepsin 1 and 3: implications in peptic ulceration. Gut 1986; 27: 243-248.
84. Valkonen K.H., Wadström T., Moran A.P. Interaction of lipopolysaccharides of Helicobacter pylori with basement protein laminin. Infect Immun 1994; 62: 3640-3648.
85. Slomiany B.L., Piotrowski J., Sengupta S., Slomiany A. Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide. Biochem Biophys Res Commun 1991; 175: 963-970.
86. Lee A., Moran A.P. Lipopolysaccharide (LPS)-related damage by H. pylori. In: Hunt R.H., Tytgat G.N.J. (Eds) Helicobacter pylori: Basic Mechanisms to Clinical Cure. Dordrecht, The Netherlands: Kluwer, 1994; 169-179.
87. Moran A.P., Heiander I.M., Kosunen T.U. Compositional analysis of Helicobacter pylori rough-form lipopolysaccharides. J Bacteriol 1992; 174: 1370-1377.
88. Moran A.P., O'Malley D.T., Kosunen T.U., Heiander I.M. Biochemical characterization of Campylobacter fetus lipopolysaccharides. Infect Immun 1994; 62: 3922-3929.
89. Yang L, Pei Z., Fujimoto S., Blaser M.J. Reattachment of surface array proteins to Campylobacter fetus cells. J Bacteriol 1992; 174: 1258-1267.
90. Mobley H.L.T., Foxall P.A. H. pylori urease. In: Hunt R.H., Tytgat G.N.J. (Eds) Helicobacter pylori: Basic Mechanisms to Clinical Cure. Dordrecht, The Netherlands: Kluwer, 1994: 41-58.
91. Moran A.P., Walsh E.J. In vitro production of endotoxin by the gastroduodenal pathogen Helicobacter pylori - relevance to serotyping. Ir J Med Sci 1993; 162: 384.
92. Moran A.P., Walsh E.J. Expression and electrophoretic characterization of smooth-form lipopolysaccharides of Helicobacter pylori. Acta Gastroenterol Belg 1993; 56 (Suppl.): 98.
93. Walsh E.J., Moran A.P. Evaluation of media for growth and antigen expression by Helicobacter pylori. Gut 1995; 37 (Suppl. 1): A17.
94. Aspinall G.O., Monteiro M.A., Pang H., Walsh E.J., Moran A.P. Lipopolysaccharide of the Helicobacter pylori type strain NCTC 11637 (ATCC 43504): structure of the O antigen chain and core oligosaccharide regions. Biochemistry 1996; 35: 2489-2497.
95. Moran A.P., McGovern J.J., Lindner B., Walsh E.J. Preliminary-structural analysis of Helicobacter pylori lipid A. Gut 1995; 37 (Suppl. 1): A16.
96. Aspinall G.O., Monteiro M.A., Moran A.P. Chemical structures of lipopolysaccharides: a window on strain to strain variations in H. pylori. Gut 1995; 37 (Suppl. 1): A17.
97. Springer G.F., Williamson P., Brandes W.C.. Blood group activity of gram-negative bacteria. J Exp Med 1961; 113: 1077-1093.
98. Mills S.D., Kurjanczyk L.A., Penner J.L. Antigenicity of Helicobacter pylori lipopolysaccharides. Infect Immun 1992; 30: 3175-3180.
99. Aspinall G.O., Monteiro M.J.V., Pang H., Walsh E.J., Moran A.P. O antigen chains in the lipopolysaccharide of Helicobacter pylori NCTC 11637. Carbohydr Lett 1994; 1: 151-156.
100. Aspinall G.O., Monteiro M.A., Moran A.P., Pang H., Penner J.L., Shaver, R.T. Lipopolysaccharides from Helicobacter pylori. Prog Clin Biol Res 1995; 392: 93-101.
101. Aspinall G.O., Monteiro M.A. Lipopolysaccharides of Helicobacter pylori strains P466 and MO19: structures of the O antigen and core oligosaccharide regions. Biochemistry 1996; 35: 2498-2504.
102. Simoons-Smit I.M., Appelmelk B.J., Verboom T. et al. Typing of Helicobacter pylori with monoclonal antibodies against Lewis antigens in lipopolysaccharide. J Clin Microbiol 1996; 34: 2196-2200.
103. x blood group antigens in human gastric carcinoma and in normal gastric tissue. Cancer Res 1989; 49: 745-752.
104. Chan N.W.C., Stangier K., Sherburne R. et al. The biosynthesis of Lewis X in Helicobacter pylori. Glycobiology 1995; 5: 683-688.
105. Appelmelk B.J., Simoons-Smit I., Negrini R. et al. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect Immun 1996; 64: 2031-2040.
106. Fan X.G., Yahoob J., Fan X.J., Keeling P.W.N. Enhanced T-helper 2 lymphocyte responses: immune mechanism of Helicobacter pylori infection. Ir J Med Sci 1996; 165: 37-39.
107. + T-cell subsets. Proc Natl Acad Sci USA 1994; 91: 18-22.
108. Mosmann T.R., Coffman R.L. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989; 46: 111-147.
109. Negrini R., Lisato L., Zanella I. et al. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa. Gastroenterology 1991; 101: 437-445.
110. Negrini R., Savio A., Poiesi C. et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology 1996; 111: 655-665.
111. Faller G., Steininger H., Eck M., Hensen J., Hahn E.G., Kirchner T. Antigastric autoantibodies in Helicobacter pylori gastritis: prevalence, in-situ binding sites and clues for clinical relevance. Virchows Arch 1996; 427: 483-486.
112. Sherburne R., Taylor D.E. Helicobacter pylori expresses a complex surface carbohydrate, Lewis X. Infect Immun 1995; 63: 4564-4568.
113. Kekki M., Siurala M., Vans K., Sipponen P., Sistonen P., Nevanlinna H.R. Classification principles and genetics of chronic gastritis. Scand J Gastroenterol 1987; 22 (Suppl. 141): 1-28.
114. Siurala M., Isokoski M., Varis K., Kekki M. Prevalence of gastritis in a rural population. Bioptic study of subjects selected at random. Scand J Gastroenterol 1968; 3: 211-223.
115. Kekki M., Villako K., Tammi A., Siurala M. Dynamics of antral and fundal gastritis in an Estonian rural population sample. Scand J Gastroenterol 1977; 12: 321-324.
116. Strickland R.G., Makay I.R. A reappraisal of the nature and significance of chronic atrophic gastritis. Dig Dis 1973; 18: 426-440.
117. +-adenosine triphosphatase of the stomach. J Clin Invest 1988; 81: 475-479.
118. Ma J.Y., Borch K., Sjöstrand S.E., Janzon L., Mårdh S. Positive correlation between H,K-adenosine triphosphatase autoantibodies and Helicobacter pylori antibodies in patients with pernicious anaemia. Scand J Gastroenterol 1994; 29: 961-965.
119. 3 Mr membrane glycoprotein. J Cell Biol 1990; 95: 563-576.
120. Goldkorn I., Gleeson P.A., Toh B.H. Gastric parietal cell antigens of 60-90,92, and 100-120 kDa associated with autoimmune gastritis and pernicious anaemia. Role of N-glycans in the structure and antigenicity of the 60-90 kDa component. J Biol Chem 1989; 264: 18768-18774.
121. Ma J.Y., Borch K., Mårdh S. Human gastric H,K-adenosine triphosphatase β-subunit is a major autoantigen in atrophic corpus gastritis. Expression of the recombinant human glycoprotein in insect cells. Scand J Gastroenterol 1994; 29: 790-794.
122. Skubitz K.M., Snook R.W. Monoclonal antibodies that recognize lacto-N-fuco-pentose III (CD15) react with the adhesion-promoting glycoprotein family (LFA-1/NMac-1/gp150,95) and CR1 on human neutrophils. J Immunol 1987; 137: 1631-1639.
123. Lund-Johansen E, Olweus J., Horejsi V. et al. Activation of human phagocytes through carbohydrate antigens (CD15, sialyl-CD15, CDw17 and CDw65). J Immunol 148: 3221-3229.
124. x) and CD15-expressing carcinoembryonic antigen-related glycoprotein NCA-160. Biochem J 1992; 288: 23-27.
125. Stöckl J., Majdic O., Rosenkranz A. et al. Monoclonal antibodies to the carbohydrate structure Lewis x stimulate the adhesive activity of leucocyte integrin CD11b/CD18 (CR3, Mac-1, α(m)β2) on human granulocytes. J Leukocyte Biol 1993; 53: 541-549.
126. x determinants on myeloid cells. Exp Parasitol 1996; 82: 191-200.
127. van Dam G.J., Claas F.H.J., Yazdanbakhsh M. et al. Schistosoma mansoni excretory antigen CCA shares carbohydrate epitopes with human granulocytes and evokes host antibodies mediating complement-dependent lysis of granulocytes. In: van Dam G.J. (Ed) Circulating Gut-associated Antigens of Schistosoma mansoni: Biological, Immunological and Molecular Aspects. Leiden, The Netherlands: University of Leiden, 1995: 174-187.